ImmTACs, a Novel Class of Soluble Bispecifics: What Have We Learned So Far?
Time: 9:30 am
day: Day Two
Details:
- Overview of the technology & challenges associated with the platform
- Clinical proof of concept
- Development of a new ImmTac against PIWIL-1, a novel colorectal cancer target
